Blue Water Life Science Advisors LP acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 90,000 shares of the company's stock, valued at approximately $3,038,000. Tempus AI makes up 2.7% of Blue Water Life Science Advisors LP's portfolio, making the stock its 8th biggest position. Blue Water Life Science Advisors LP owned about 0.06% of Tempus AI at the end of the most recent quarter.
A number of other large investors have also made changes to their positions in the stock. Victory Capital Management Inc. acquired a new position in shares of Tempus AI in the 4th quarter valued at $216,000. China Universal Asset Management Co. Ltd. purchased a new stake in Tempus AI during the fourth quarter valued at about $1,091,000. Mirae Asset Global Investments Co. Ltd. acquired a new stake in Tempus AI during the fourth quarter worth about $178,000. abrdn plc acquired a new stake in Tempus AI during the fourth quarter worth about $2,784,000. Finally, Dakota Wealth Management raised its holdings in shares of Tempus AI by 189.7% in the 4th quarter. Dakota Wealth Management now owns 60,668 shares of the company's stock worth $2,048,000 after purchasing an additional 39,724 shares during the period. Institutional investors and hedge funds own 24.22% of the company's stock.
Tempus AI Stock Performance
Shares of Tempus AI stock traded up $2.87 on Tuesday, hitting $43.85. The company had a trading volume of 6,006,098 shares, compared to its average volume of 5,534,456. The company has a current ratio of 2.69, a quick ratio of 2.55 and a debt-to-equity ratio of 8.17. Tempus AI, Inc. has a 52 week low of $22.89 and a 52 week high of $91.45. The business has a 50-day simple moving average of $52.83 and a 200-day simple moving average of $50.44.
Insider Activity
In other news, CAO Ryan M. Bartolucci sold 818 shares of the stock in a transaction on Wednesday, February 19th. The stock was sold at an average price of $81.87, for a total transaction of $66,969.66. Following the completion of the sale, the chief accounting officer now owns 46,182 shares in the company, valued at approximately $3,780,920.34. This represents a 1.74 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Nadja West sold 809 shares of Tempus AI stock in a transaction dated Tuesday, March 4th. The stock was sold at an average price of $51.11, for a total value of $41,347.99. Following the completion of the transaction, the director now directly owns 37,705 shares in the company, valued at $1,927,102.55. This represents a 2.10 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 5,146,249 shares of company stock worth $301,185,058 over the last 90 days.
Analyst Upgrades and Downgrades
Several research firms have commented on TEM. Guggenheim reissued a "buy" rating on shares of Tempus AI in a research report on Tuesday, February 25th. JPMorgan Chase & Co. cut shares of Tempus AI from an "overweight" rating to a "neutral" rating and upped their price objective for the company from $50.00 to $55.00 in a research report on Tuesday, February 25th. William Blair reiterated a "market perform" rating on shares of Tempus AI in a research note on Tuesday, February 25th. Needham & Company LLC restated a "buy" rating and set a $70.00 price objective on shares of Tempus AI in a report on Thursday, April 10th. Finally, BTIG Research started coverage on Tempus AI in a research note on Monday. They issued a "buy" rating and a $60.00 price target for the company. Six equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company's stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $61.08.
Get Our Latest Report on TEM
About Tempus AI
(
Free Report)
Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.
Recommended Stories
Before you consider Tempus AI, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tempus AI wasn't on the list.
While Tempus AI currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
